Press Releases WuXi AppTec Co., Ltd.

Stocks

603259

CNE1000031K4

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 21/07/2026			5-day change	1st Jan Change
126.45 ^CNY	+1.80%		-0.83%	+39.51%

10/07	Nomura Adjusts WuXi AppTec's Price Target to HK$180.22 From HK$157.07, Keeps at Buy	MT
10/07	Nomura Adjusts WuXi AppTec's Price Target to 164 Yuan From 142.93 Yuan, Keeps at Buy	MT

Press Releases

05:27am	WuXi AppTec : Named Constituent of the FTSE4Good Index Series for Fourth Consecutive Year	PU
07/07	Integrated Development Helps Targeted Protein Degraders Reach the Clinic	AQ
25/06	WuXi AppTec Added To DOW's 1260H List: The BIOSECURE Act Clock Is Running	AQ
12/06	WuXi AppTec : An Update on Our Legal Action Challenging 1260H Designation	PU
09/06	Peptides for Women: 7 Providers Worth Considering in 2026	AQ
09/06	WuXi AppTec : An open letter to our customers	PU
18/05	WuXi AppTec : Recognized as a Top-Performing Company on 2026 Dow Jones Best-in-Class World Index	PU
27/04	WuXi AppTec : WXAT 2026Q1 Results Presentation	PU
17/04	Science Knows No Borders: How Does WuXi AppTec Empower Innovation Across Regions	AQ
13/04	WuXi AppTec : WXAT 2025 Annual Results Presentation	PU
23/03	WuXi AppTec : WXAT 2025 Annual Results Presentation	PU
19/01	WuXi AppTec Receives Double 'A' Rating from CDP for Climate Change and Water Security Leadership	AQ
15/01	WuXi AppTec : 2026 JPM Presentation - WuXi AppTec 20260114	PU
12/01	WuXi AppTec : Issues Positive Profit Alert for the Full Year of 2025	PU
21/11	WuXi AppTec Receives Frost & Sullivan's 2025 Global Company of the Year Recognition in the CRDMO Industry	AQ
26/25/26	WuXi AppTec : Achieves Strong Double-Digit Growth in Revenue and Profit for Q1-Q3 2025; Backlog for Continuing Operations Up 41.2% YoY; Further Raises 2025 Full-year Guidance	PU
26/25/26	WuXi AppTec : Achieves Strong Double-Digit Growth in Revenue and Profit for Q1-Q3 2025; Backlog for Continuing Operations Up 41.2% YoY Further Raises 2025 Full-year Guidance	PU
26/25/26	WuXi AppTec : Unveils Modernized Logo, Reflecting Continued Evolution as a Global Healthcare Partner	PU
26/25/26	WuXi AppTec : 2025 Third Quarterly Results Presentation	PU
26/25/26	WuXi AppTec : Signs Definitive Agreement to Sell China-based Clinical Research Services Business to Hillhouse	PU
14/25/14	BIOSECURE Included In Draft National Defense Authorization Act Of 2026	AQ
26/25/26	WuXi AppTec : 2025 WuXi AppTec Investor Day - Financial Performance	PU
26/25/26	WuXi AppTec : 2025 WuXi AppTec Investor Day - Research Enabling Platforms	PU
28/25/28	WuXi AppTec : Completes Second RMB1.0 Billion A-Share Repurchase Program in 2025, All Repurchased Shares to Be Cancelled	PU
28/25/28	WuXi AppTec : Achieves Strong Growth in Revenue and Profit for Q2 and H1 2025, H1 Revenue from Continuing Operations Up 24.2% YoY, and Adjusted Non-IFRS Net Profit Up 44.4% YoY; Backlog for Continuing Operations Up 37.2% YoY	PU